NASDAQ · Medical - Healthcare Information Services

GeneDx Holdings Corp. (WGS) Stock

$67.33 -0.59% NASDAQ: WGS Healthcare

Valuation

MetricValue
Price$67.33
Market Cap$2.01B
P/E Ratio-19.86
P/B Ratio8.80
P/S Ratio4.74
EPS (TTM)$-0.73
52-Week High$170.87
52-Week Low$32.21
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-38.72%
ROA-22.09%
ROCE-14.90%
Gross Margin69.74%
Operating Margin-2.76%
Net Margin-23.40%
Debt/Equity0.69
Current Ratio2.46

Annual Financials (USD)

Metric20212022202320242025
Revenue$212.0M$235.0M$203.0M$305.0M$428.0M
Operating Profit$-446.0M$-668.0M$-181.0M$-23.0M$-12.0M
Net Profit$-245.0M$-549.0M$-176.0M$-52.0M$-21.0M
EPS$-74.93$-53.63$-7.23$-1.94$-0.73
Op Margin-210.3%-284.5%-89.2%-7.6%-2.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$554.0M$545.0M$419.0M$419.0M$570.0M
Total Liabilities$166.0M$292.0M$191.0M$174.0M$262.0M
Cash$401.0M$137.0M$100.0M$85.0M$105.0M
Borrowings$33.0M$77.0M$120.0M$116.0M$152.0M

Latest News

GeneDx Holdings Corp. (WGS) Slid as Revenue Fell Short of Expectations Insider Monkey · Jul 21, 2026 GeneDx Holdings Corp. (WGS) Fell Following a Significant Cut in 2026 Guidance Insider Monkey · Jul 17, 2026 GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026 Business Wire · Jul 16, 2026 What a $227,000 GeneDx Insider Sale Means as Revenue Climbs 17% Motley Fool · Jun 23, 2026 GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth Business Wire · Jun 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-190.0M$-319.0M$-180.0M$-28.0M$33.0M
Investing Cash Flow$-42.0M$-156.0M$-49.0M$-36.0M$-81.0M
Financing Cash Flow$65.0M$3.0M$0$1.0M$0
Net Cash Flow$283.0M$-263.0M$-38.0M$-14.0M$20.0M
Free Cash Flow$-211.0M$-333.0M$-186.0M$-34.0M$14.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-29.61
FCF Yield-3.52%
Quick Ratio3.06
Interest Coverage-20.31
Return 1Y-24.14%
Return 3Y708.87%
Return 5Y-83.92%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AIDX20/20 Biolabs, Inc. $0.38 -1.06% -0.46 $4.59M 0.00%
BLLNBillionToOne, Inc. $98.09 +2.81% 154.24 $4.51B 0.00%
CSTLCastle Biosciences, Inc. $34.42 +2.11% -53.92 $1.05B 0.00%
FLGTFulgent Genetics, Inc. $21.74 +4.42% -7.62 $617.43M 0.00%
IMDXInsight Molecular Diagnostics Inc. $3.37 +2.74% -2.12 $108.82M 0.00%

About GeneDx Holdings Corp.

GeneDx Holdings Corp. is led by CEO Katherine A. Stueland, employs 1,000 people, headquartered in US, publicly traded since 2020.

GeneDx Holdings Corp. (WGS) stock trades at $67.33 with a market capitalization of $2.01B. The stock is valued at a price-to-earnings (P/E) ratio of -19.86, price-to-book of 8.80, price-to-sales of 4.74. Over the past 52 weeks the stock has ranged between $32.21 and $170.87, and currently trades 60.6% below its 52-week high.

On profitability, GeneDx Holdings Corp. generates a return on equity (ROE) of -38.72%, return on capital employed of -14.90%, an operating margin of -2.76%, a net profit margin of -23.40%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides